Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community

  Life Technologies and RainTree Oncology Services Announce Collaboration to
            Bring Molecular Tumor Testing to Community Oncologists

Development of comprehensive oncology database will assist community
oncologists with access to early phase clinical trials

PR Newswire

CARLSBAD, Calif., Aug. 5, 2013

CARLSBAD, Calif., Aug. 5, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) and RainTree Oncology Services today announced they have
entered into a collaboration agreement designed to further the advancement of
personalized care for cancer patients.

Through the collaboration, RainTree and Life Technologies will seek to make
the latest advances in molecular testing available to the broader patient
market and will work to develop a streamlined protocol for entering patients
into clinical trials for new targeted therapies.

Key elements of the collaboration are:

  oCollaborate on matching oncology patients to clinical trials using a Next
    Generation Sequencing Oncology screening panel;
  oDevelop a clinical trials recruitment database which incorporates
    RainTree's broad patient data set, enhanced by other data sources,
    including Life's Compendia analytics engine;
  oEducate private payors and health plans about the benefits of Next
    Generation Sequencing; and
  oBuild and market comprehensive product, test and data offerings for
    clinical research organizations.

"Today's announcement emphasizes RainTree Oncology Services' commitment to
providing access to cutting edge capabilities to the over 600 community
oncologists and approximately 40 practices that we serve," said Mike Martin,
chief executive officer of RainTree. "The world of personalized medicine is
moving very fast, and the collaboration with Life Technologies ensures we stay
active in the development of advanced molecular diagnostic capabilities to
connect our physicians and patients with the latest in therapeutic discovery."

"Our goal is to ensure that patients in the community setting have the same
access to advanced technologies, such as genetic sequencing, as patients in
the top academic centers," said Ronnie Andrews, president of genetic and
medical sciences at Life Technologies. "This collaboration also establishes a
mechanism for pharmaceutical companies to identify the patients they need for
clinical trials to bring new, targeted therapies to market."

"Life Technologies and RainTree Oncology share a mutual commitment to
improving cancer care in the community setting, where the majority of patients
are diagnosed and treated," said Andrews.

Through the collaboration, Life Technologies intends to participate in
development of next generation sequencing panels that will allow for deep
interrogation of tumors. Additional assays may also be developed under the
collaboration. Patient data will be housed in a de-identified format in a
proprietary database, which will be made available to pharmaceutical companies
to recruit Phase 1 patients, as well as to participating clinical research
organizations to support recruitment for later phase trials.

The agreement provides for RainTree and Life Technologies to leverage
RainTree's data sets, and utilize the information to enrich patient
populations for early phase clinical trials and apply advanced bioinformatics
techniques via Life Technologies' proprietary Compendia Oncomine® solution to
help identify targeted therapeutics for trials on certain tumor genotypes.

More than one half of cancer patients are seen in community oncology
practices, according to Inside Oncology, Academic Cancer Centers (NCCC). The
more than 500 new targeted compounds currently in development are leading to a
large unmet need for recruitment of patients based on specific molecular
profiles. 

"Efficiently identifying clinical trial candidates for new targeted therapies
has presented an obstacle in bringing new drugs to market," said Dr. Jeff
Patton, chief medical officer of RainTree and chief executive officer of
Tennessee Oncology. "Through our collaboration with Life Technologies, we will
be able to tap into new genetic information that, along with our existing data
sets, will help guide patients to enroll in clinical trials based on the
genetic signatures of their tumors."

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with the Securities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

About RainTree Oncology Services

RainTree Oncology is the nation's leading community oncology alliance,
assisting its member practices in achieving better and more cost-effective
treatment of oncology care while creating new streams of revenue for these
community oncology practices. RainTree Oncology Services achieves this by
negotiating and administering favorable GPO contracts, creating a unique
aggregated data warehouse and analytic platform to develop and evaluate care
pathways while reducing the cost to the health care system, developing
commercial relationships and accelerating innovative oncology treatments and
payor arrangements while optimizing patient care and advancing the science of
oncology. For more information about RainTree Oncology Services visit
www.raintreeoncology.com.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO )

Life Technologies Contact:
Suzanne Clancy
858-205-4235 (mobile)
suzanne.clancy@lifetech.com

RainTree Oncology Services Contact:
John Creelman
858-436-7473
jcreelman@raintreeoncology.com

SOURCE Life Technologies Corporation

Website: http://www.lifetechnologies.com